EXHIBIT 31.1

       CERTIFICATIONS UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Georges Benarroch, certify that:

     1.   I have reviewed this annual report on Form 10-KSB of Kyto Biopharma,
          Inc.;

     2.   Based on my knowledge, this report does not contain any untrue
          statement of a material fact or omit to state a material fact
          necessary to make the statements made, in light of the circumstances
          under which such statements were made, not misleading with respect to
          the period covered by this report;

     3.   Based on my knowledge, the financial statements, and other financial
          information included in this report, fairly present in all material
          respects the financial condition, results of operations and cash flows
          of the registrant as of, and for, the periods presented in this
          report;

     4.   I am responsible for establishing and maintaining disclosure controls
          and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14)
          for the small business issuer and have:

          a)   designed such disclosure controls and procedures to ensure that
               material information relating to the small business issuer,
               including its consolidated subsidiary, is made known to us by
               others within those entities, particularly during the period in
               which this report is being prepared;

          b)   evaluated the effectiveness of the small business issuer's
               disclosure controls and procedures as of a date within 90 days
               prior to the filing date of this report (the "Evaluation Date");
               and

          c)   presented in this annual report our conclusions about the
               effectiveness of the disclosure controls and procedures based on
               our evaluation as of the Evaluation Date;

     5.   I have disclosed, based on our most recent evaluation, to the small
          business issuer's auditors and the audit committee of registrant's
          board of directors (or persons performing the equivalent function):

          a)   all significant deficiencies in the design or operation of
               internal controls which could adversely affect the small business
               issuer 's ability to record, process, summarize and report
               financial data and have identified for the registrant's auditors
               any material weaknesses in internal controls; and

          b)   any fraud, whether or not material, that involves management or
               other employees who have a significant role in the small business
               issuer's internal controls; and

     6.   I have indicated in this report whether or not there were significant
          changes in internal controls or in other factors that could
          significantly affect internal controls subsequent to the date of our
          most recent evaluation, including any corrective actions with regard
          to significant deficiencies and material weaknesses.


                                          Date:  June 27, 2007



                                          By: /s/ Georges Benarroch
                                              ----------------------------------
                                              Georges Benarroch
                                              President, Chief Executive Officer
                                              and Acting Chief Financial Officer